

Updates to the Alberta Drug Benefit List

Effective April 1, 2015



Inquiries should be directed to:

Pharmacy Services

Alberta Blue Cross
10009 108 Street NW
Edmonton AB T5J 3C5

Telephone Number: (780) 498-8370 (Edmonton)
(403) 294-4041 (Calgary)
1-800-361-9632 (Toll Free)

FAX Number: (780) 498-8384
1-877-828-4106 (Toll Free)

Website: <http://www.health.alberta.ca/services/drug-benefit-list.html>

Administered by Alberta Blue Cross
on behalf of Alberta Health.

The Drug Benefit List (DBL) is a list of drugs for which coverage may be provided to program participants. The DBL is not intended to be, and must not be used as a diagnostic or prescribing tool. Inclusion of a drug on the DBL does not mean or imply that the drug is fit or effective for any specific purpose. Prescribing professionals must always use their professional judgment and should refer to product monographs and any applicable practice guidelines when prescribing drugs. The product monograph contains information that may be required for the safe and effective use of the product.

Copies of the *Alberta Drug Benefit List* Publication are available from Pharmacy Services, Alberta Blue Cross at the address shown above.

Binder and contents: **\$42.00** (\$40.00 + \$2.00 G.S.T.)
Contents only: **\$36.75** (\$35.00 + \$1.75 G.S.T.)

A cheque or money order must accompany the request for copies.

Table of Contents

Added Product(s)	1
Least Cost Alternative (LCA) Price Change(s)	1
Part 2 Drug Additions	2-1
Part 3 Special Authorization	3-1

Added Product(s)

Trade Name / Strength / Form	Generic Description	DIN	MFR
ECL-CITALOPRAM 10 MG TABLET	CITALOPRAM HYDROBROMIDE	00002421739	ECL
ECL-CITALOPRAM 20 MG TABLET	CITALOPRAM HYDROBROMIDE	00002421747	ECL
ECL-CITALOPRAM 40 MG TABLET	CITALOPRAM HYDROBROMIDE	00002421755	ECL

Least Cost Alternative (LCA) Price Change(s)

As a result of the Pan-Canadian Competitive Value Price Initiative for Generic Drugs, the following established IC Grouping(s) are affected and a revised LCA price has been established and will be applied effective April 1, 2015.

Please review the online Alberta Drug Benefit List at <http://www.health.alberta.ca/services/drug-benefit-list.html> for further information.

Generic Description	Strength / Form	New LCA Price
CLOPIDOGREL BISULFATE	75 MG TABLET	0.4735
GABAPENTIN	100 MG CAPSULE	0.0749
GABAPENTIN	300 MG CAPSULE	0.1821
GABAPENTIN	400 MG CAPSULE	0.2171
METFORMIN HCL	500 MG TABLET	0.0444
METFORMIN HCL	850 MG TABLET	0.0610
OLANZAPINE	2.5 MG TABLET	0.3189
OLANZAPINE	5 MG TABLET	0.6379
OLANZAPINE	7.5 MG TABLET	0.9568
OLANZAPINE	10 MG TABLET	1.2758
OLANZAPINE	15 MG TABLET	1.9136
OLANZAPINE	5 MG DISINTEGRATING TABLET	0.6434
OLANZAPINE	10 MG DISINTEGRATING TABLET	1.2857

PART 2

Drug Additions

ALBERTA DRUG BENEFIT LIST UPDATE

AMLODIPINE BESYLATE

2.5 MG (BASE) ORAL TABLET

00002297477	ACT AMLODIPINE	APH	\$	0.1380
00002385783	AMLODIPINE	SIV	\$	0.1380
00002357186	JAMP-AMLODIPINE	JPC	\$	0.1380
00002295148	PMS-AMLODIPINE	PMS	\$	0.1380
00002330474	SANDOZ AMLODIPINE	SDZ	\$	0.1380

5 MG (BASE) ORAL TABLET

00002297485	ACT AMLODIPINE	APH	\$	0.2417
00002331284	AMLODIPINE	SNS	\$	0.2417
00002331934	AMLODIPINE	RAN	\$	0.2417
00002385791	AMLODIPINE	SIV	\$	0.2417
00002429217	AMLODIPINE	JPC	\$	0.2417
00002273373	APO-AMLODIPINE	APX	\$	0.2417
00002397072	AURO-AMLODIPINE	AUR	\$	0.2417
00002280132	GD-AMLODIPINE	GMD	\$	0.2417
00002357194	JAMP-AMLODIPINE	JPC	\$	0.2417
00002371715	MAR-AMLODIPINE	MAR	\$	0.2417
00002362651	MINT-AMLODIPINE	MPI	\$	0.2417
00002272113	MYLAN-AMLODIPINE	MYP	\$	0.2417
00002284065	PMS-AMLODIPINE	PMS	\$	0.2417
00002321858	RAN-AMLODIPINE	RAN	\$	0.2417
00002259605	RATIO-AMLODIPINE	RPH	\$	0.2417
00002284383	SANDOZ AMLODIPINE	SDZ	\$	0.2417
00002357712	SEPTA-AMLODIPINE	SEP	\$	0.2417
00002250497	TEVA-AMLODIPINE	TEV	\$	0.2417
00000878928	NORVASC	PFI	\$	1.3426

10 MG (BASE) ORAL TABLET

00002297493	ACT AMLODIPINE	APH	\$	0.3587
00002331292	AMLODIPINE	SNS	\$	0.3587
00002331942	AMLODIPINE	RAN	\$	0.3587
00002385805	AMLODIPINE	SIV	\$	0.3587
00002429225	AMLODIPINE	JPC	\$	0.3587
00002273381	APO-AMLODIPINE	APX	\$	0.3587
00002397080	AURO-AMLODIPINE	AUR	\$	0.3587
00002280140	GD-AMLODIPINE	GMD	\$	0.3587
00002357208	JAMP-AMLODIPINE	JPC	\$	0.3587
00002371723	MAR-AMLODIPINE	MAR	\$	0.3587
00002362678	MINT-AMLODIPINE	MPI	\$	0.3587
00002272121	MYLAN-AMLODIPINE	MYP	\$	0.3587
00002284073	PMS-AMLODIPINE	PMS	\$	0.3587
00002321866	RAN-AMLODIPINE	RAN	\$	0.3587
00002259613	RATIO-AMLODIPINE	RPH	\$	0.3587
00002284391	SANDOZ AMLODIPINE	SDZ	\$	0.3587
00002357720	SEPTA-AMLODIPINE	SEP	\$	0.3587
00002250500	TEVA-AMLODIPINE	TEV	\$	0.3587
00000878936	NORVASC	PFI	\$	1.9930

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

ALBERTA DRUG BENEFIT LIST UPDATE

ATORVASTATIN CALCIUM

10 MG (BASE) ORAL TABLET

00002310899	ACT ATORVASTATIN	APH	\$	0.3138
00002295261	APO-ATORVASTATIN	APX	\$	0.3138
00002348705	ATORVASTATIN	SNS	\$	0.3138
00002411350	ATORVASTATIN-10	SIV	\$	0.3138
00002288346	GD-ATORVASTATIN	GMD	\$	0.3138
00002391058	JAMP-ATORVASTATIN	JPC	\$	0.3138
00002373203	MYLAN-ATORVASTATIN	MYP	\$	0.3138
00002392933	MYLAN-ATORVASTATIN	MYP	\$	0.3138
00002302675	NOVO-ATORVASTATIN	TEV	\$	0.3138
00002399377	PMS-ATORVASTATIN	PMS	\$	0.3138
00002313707	RAN-ATORVASTATIN	RAN	\$	0.3138
00002350297	RATIO-ATORVASTATIN	RPH	\$	0.3138
00002324946	SANDOZ ATORVASTATIN	SDZ	\$	0.3138
00002230711	LIPITOR	PFI	\$	1.7692

20 MG (BASE) ORAL TABLET

00002310902	ACT ATORVASTATIN	APH	\$	0.3922
00002295288	APO-ATORVASTATIN	APX	\$	0.3922
00002348713	ATORVASTATIN	SNS	\$	0.3922
00002411369	ATORVASTATIN-20	SIV	\$	0.3922
00002288354	GD-ATORVASTATIN	GMD	\$	0.3922
00002391066	JAMP-ATORVASTATIN	JPC	\$	0.3922
00002373211	MYLAN-ATORVASTATIN	MYP	\$	0.3922
00002392941	MYLAN-ATORVASTATIN	MYP	\$	0.3922
00002302683	NOVO-ATORVASTATIN	TEV	\$	0.3922
00002399385	PMS-ATORVASTATIN	PMS	\$	0.3922
00002313715	RAN-ATORVASTATIN	RAN	\$	0.3922
00002350319	RATIO-ATORVASTATIN	RPH	\$	0.3922
00002324954	SANDOZ ATORVASTATIN	SDZ	\$	0.3922
00002230713	LIPITOR	PFI	\$	2.2115

40 MG (BASE) ORAL TABLET

00002310910	ACT ATORVASTATIN	APH	\$	0.4216
00002295296	APO-ATORVASTATIN	APX	\$	0.4216
00002348721	ATORVASTATIN	SNS	\$	0.4216
00002411377	ATORVASTATIN-40	SIV	\$	0.4216
00002288362	GD-ATORVASTATIN	GMD	\$	0.4216
00002391074	JAMP-ATORVASTATIN	JPC	\$	0.4216
00002373238	MYLAN-ATORVASTATIN	MYP	\$	0.4216
00002392968	MYLAN-ATORVASTATIN	MYP	\$	0.4216
00002302691	NOVO-ATORVASTATIN	TEV	\$	0.4216
00002399393	PMS-ATORVASTATIN	PMS	\$	0.4216
00002313723	RAN-ATORVASTATIN	RAN	\$	0.4216
00002350327	RATIO-ATORVASTATIN	RPH	\$	0.4216
00002324962	SANDOZ ATORVASTATIN	SDZ	\$	0.4216
00002230714	LIPITOR	PFI	\$	2.3770

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

ALBERTA DRUG BENEFIT LIST UPDATE

ATORVASTATIN CALCIUM

80 MG (BASE)	ORAL TABLET			
00002310929	ACT ATORVASTATIN	APH	\$	0.4216
00002295318	APO-ATORVASTATIN	APX	\$	0.4216
00002348748	ATORVASTATIN	SNS	\$	0.4216
00002411385	ATORVASTATIN-80	SIV	\$	0.4216
00002288370	GD-ATORVASTATIN	GMD	\$	0.4216
00002391082	JAMP-ATORVASTATIN	JPC	\$	0.4216
00002373246	MYLAN-ATORVASTATIN	MYP	\$	0.4216
00002392976	MYLAN-ATORVASTATIN	MYP	\$	0.4216
00002302713	NOVO-ATORVASTATIN	TEV	\$	0.4216
00002399407	PMS-ATORVASTATIN	PMS	\$	0.4216
00002313758	RAN-ATORVASTATIN	RAN	\$	0.4216
00002350335	RATIO-ATORVASTATIN	RPH	\$	0.4216
00002324970	SANDOZ ATORVASTATIN	SDZ	\$	0.4216
00002243097	LIPITOR	PFI	\$	2.3770

CITALOPRAM HYDROBROMIDE

10 MG (BASE)	ORAL TABLET			
00002414570	ABBOTT-CITALOPRAM	ABB	\$	0.1432
00002355248	ACCEL-CITALOPRAM	ACP	\$	0.1432
00002421739	ECL-CITALOPRAM	ECL	\$	0.1432
00002370085	JAMP-CITALOPRAM	JPC	\$	0.1432
00002371871	MAR-CITALOPRAM	MAR	\$	0.1432
00002370077	MINT-CITALOPRAM	MPI	\$	0.1432
00002270609	PMS-CITALOPRAM	PMS	\$	0.1432
00002312336	TEVA-CITALOPRAM	TEV	\$	0.1432
20 MG (BASE)	ORAL TABLET			
00002414589	ABBOTT-CITALOPRAM	ABB	\$	0.2397
00002355256	ACCEL-CITALOPRAM	ACP	\$	0.2397
00002248050	ACT CITALOPRAM	APH	\$	0.2397
00002246056	APO-CITALOPRAM	APX	\$	0.2397
00002275562	AURO-CITALOPRAM	AUR	\$	0.2397
00002331950	CITALOPRAM	RAN	\$	0.2397
00002353660	CITALOPRAM	SNS	\$	0.2397
00002387956	CITALOPRAM	SIV	\$	0.2397
00002430541	CITALOPRAM	JPC	\$	0.2397
00002306239	CITALOPRAM-ODAN	ODN	\$	0.2397
00002421747	ECL-CITALOPRAM	ECL	\$	0.2397
00002313405	JAMP-CITALOPRAM	JPC	\$	0.2397
00002371898	MAR-CITALOPRAM	MAR	\$	0.2397
00002304686	MINT-CITALOPRAM	MPI	\$	0.2397
00002246594	MYLAN-CITALOPRAM	MYP	\$	0.2397
00002409011	NAT-CITALOPRAM	NTP	\$	0.2397
00002248010	PMS-CITALOPRAM	PMS	\$	0.2397
00002285622	RAN-CITALO	RAN	\$	0.2397
00002252112	RATIO-CITALOPRAM	RPH	\$	0.2397
00002248170	SANDOZ CITALOPRAM	SDZ	\$	0.2397
00002355272	SEPTA-CITALOPRAM	SEP	\$	0.2397
00002293218	TEVA-CITALOPRAM	TEV	\$	0.2397
00002239607	CELEXA	LBC	\$	1.3437

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

CITALOPRAM HYDROBROMIDE

40 MG (BASE)	ORAL TABLET			
00002414597	ABBOTT-CITALOPRAM	ABB	\$	0.2397
00002355264	ACCEL-CITALOPRAM	ACP	\$	0.2397
00002248051	ACT CITALOPRAM	APH	\$	0.2397
00002246057	APO-CITALOPRAM	APX	\$	0.2397
00002275570	AURO-CITALOPRAM	AUR	\$	0.2397
00002331977	CITALOPRAM	RAN	\$	0.2397
00002353679	CITALOPRAM	SNS	\$	0.2397
00002387964	CITALOPRAM	SIV	\$	0.2397
00002430568	CITALOPRAM	JPC	\$	0.2397
00002306247	CITALOPRAM-ODAN	ODN	\$	0.2397
00002421755	ECL-CITALOPRAM	ECL	\$	0.2397
00002313413	JAMP-CITALOPRAM	JPC	\$	0.2397
00002371901	MAR-CITALOPRAM	MAR	\$	0.2397
00002304694	MINT-CITALOPRAM	MPI	\$	0.2397
00002246595	MYLAN-CITALOPRAM	MYP	\$	0.2397
00002409038	NAT-CITALOPRAM	NTP	\$	0.2397
00002248011	PMS-CITALOPRAM	PMS	\$	0.2397
00002285630	RAN-CITALO	RAN	\$	0.2397
00002252120	RATIO-CITALOPRAM	RPH	\$	0.2397
00002248171	SANDOZ CITALOPRAM	SDZ	\$	0.2397
00002355280	SEPTA-CITALOPRAM	SEP	\$	0.2397
00002293226	TEVA-CITALOPRAM	TEV	\$	0.2397
00002239608	CELEXA	LBC	\$	1.3437

CLOPIDOGREL BISULFATE

LIMITED RESTRICTED BENEFIT - This product is a benefit for patients for the prevention of thrombosis, following intravascular stent placement, when prescribed by a Specialist in Cardiology, Cardiac Surgery, Cardiovascular & Thoracic Surgery, or General Surgery. This benefit is limited to one month of coverage for the first stent placement only. (For eligibility for repeat stents, other indications, or continued coverage up to 12 months following intravascular drug eluting stent (DES) placement refer to Criteria for Special Authorization of Select Drug Products of the List and Criteria for Special Authorization of Select Drug Products of the Alberta Human Services Drug Benefit Supplement for Alberta Human Services clients.)

75 MG (BASE)	ORAL TABLET			
00002412942	ABBOTT-CLOPIDOGREL	ABB	\$	0.4735
00002252767	APO-CLOPIDOGREL	APX	\$	0.4735
00002416387	AURO-CLOPIDOGREL	AUR	\$	0.4735
00002385813	CLOPIDOGREL	SIV	\$	0.4735
00002400553	CLOPIDOGREL	SNS	\$	0.4735
00002303027	CO CLOPIDOGREL	APH	\$	0.4735
00002415550	JAMP-CLOPIDOGREL	JPC	\$	0.4735
00002422255	MAR-CLOPIDOGREL	MAR	\$	0.4735
00002408910	MINT-CLOPIDOGREL	MPI	\$	0.4735
00002351536	MYLAN-CLOPIDOGREL	MYP	\$	0.4735
00002348004	PMS-CLOPIDOGREL	PMS	\$	0.4735
00002379813	RAN-CLOPIDOGREL	RAN	\$	0.4735
00002359316	SANDOZ CLOPIDOGREL	SDZ	\$	0.4735
00002293161	TEVA-CLOPIDOGREL	TEV	\$	0.4735
00002238682	PLAVIX	SAV	\$	2.7125

ALBERTA DRUG BENEFIT LIST UPDATE

GABAPENTIN

100 MG ORAL CAPSULE

00002244304	APO-GABAPENTIN	APX	\$	0.0749
00002321203	AURO-GABAPENTIN	AUR	\$	0.0749
00002256142	CO GABAPENTIN	APH	\$	0.0749
00002246314	GABAPENTIN	SIV	\$	0.0749
00002332582	GABAPENTIN	RAN	\$	0.0749
00002353245	GABAPENTIN	SNS	\$	0.0749
00002416840	GABAPENTIN	AHI	\$	0.0749
00002285819	GD-GABAPENTIN	GMD	\$	0.0749
00002361469	JAMP-GABAPENTIN	JPC	\$	0.0749
00002391473	MAR-GABAPENTIN	MAR	\$	0.0749
00002248259	MYLAN-GABAPENTIN	MYP	\$	0.0749
00002243446	PMS-GABAPENTIN	PMS	\$	0.0749
00002319055	RAN-GABAPENTIN	RAN	\$	0.0749
00002260883	RATIO-GABAPENTIN	RPH	\$	0.0749
00002244513	TEVA-GABAPENTIN	TEV	\$	0.0749
00002084260	NEURONTIN	PFI	\$	0.4285

300 MG ORAL CAPSULE

00002244305	APO-GABAPENTIN	APX	\$	0.1821
00002321211	AURO-GABAPENTIN	AUR	\$	0.1821
00002256150	CO GABAPENTIN	APH	\$	0.1821
00002246315	GABAPENTIN	SIV	\$	0.1821
00002332590	GABAPENTIN	RAN	\$	0.1821
00002353253	GABAPENTIN	SNS	\$	0.1821
00002416859	GABAPENTIN	AHI	\$	0.1821
00002285827	GD-GABAPENTIN	GMD	\$	0.1821
00002361485	JAMP-GABAPENTIN	JPC	\$	0.1821
00002391481	MAR-GABAPENTIN	MAR	\$	0.1821
00002248260	MYLAN-GABAPENTIN	MYP	\$	0.1821
00002243447	PMS-GABAPENTIN	PMS	\$	0.1821
00002319063	RAN-GABAPENTIN	RAN	\$	0.1821
00002244514	TEVA-GABAPENTIN	TEV	\$	0.1821
00002084279	NEURONTIN	PFI	\$	1.0425

400 MG ORAL CAPSULE

00002244306	APO-GABAPENTIN	APX	\$	0.2171
00002321238	AURO-GABAPENTIN	AUR	\$	0.2171
00002256169	CO GABAPENTIN	APH	\$	0.2171
00002246316	GABAPENTIN	SIV	\$	0.2171
00002332604	GABAPENTIN	RAN	\$	0.2171
00002353261	GABAPENTIN	SNS	\$	0.2171
00002416867	GABAPENTIN	AHI	\$	0.2171
00002285835	GD-GABAPENTIN	GMD	\$	0.2171
00002361493	JAMP-GABAPENTIN	JPC	\$	0.2171
00002391503	MAR-GABAPENTIN	MAR	\$	0.2171
00002248261	MYLAN-GABAPENTIN	MYP	\$	0.2171
00002243448	PMS-GABAPENTIN	PMS	\$	0.2171
00002319071	RAN-GABAPENTIN	RAN	\$	0.2171
00002260905	RATIO-GABAPENTIN	RPH	\$	0.2171
00002244515	TEVA-GABAPENTIN	TEV	\$	0.2171
00002084287	NEURONTIN	PFI	\$	1.2424

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

ALBERTA DRUG BENEFIT LIST UPDATE

METFORMIN HCL

500 MG ORAL TABLET

00002167786	APO-METFORMIN	APX	\$	0.0444
00002257726	CO METFORMIN	APH	\$	0.0444
00002421828	ECL-METFORMIN	ECL	\$	0.0444
00002380196	JAMP-METFORMIN	JPC	\$	0.0444
00002380722	JAMP-METFORMIN BLACKBERRY	JPC	\$	0.0444
00002378620	MAR-METFORMIN	MAR	\$	0.0444
00002353377	METFORMIN	SNS	\$	0.0444
00002378841	METFORMIN	MAR	\$	0.0444
00002385341	METFORMIN FC	SIV	\$	0.0444
00002388766	MINT-METFORMIN	MPI	\$	0.0444
00002148765	MYLAN-METFORMIN	MYP	\$	0.0444
00002223562	PMS-METFORMIN	PMS	\$	0.0444
00002269031	RAN-METFORMIN	RAN	\$	0.0444
00002242974	RATIO-METFORMIN HYDROCHLORIDE	RPH	\$	0.0444
00002246820	SANDOZ METFORMIN FC	SDZ	\$	0.0444
00002379767	SEPTA-METFORMIN	SEP	\$	0.0444
00002045710	TEVA-METFORMIN	TEV	\$	0.0444
00002099233	GLUCOPHAGE	SAV	\$	0.2716

850 MG ORAL TABLET

00002229785	APO-METFORMIN	APX	\$	0.0610
00002257734	CO METFORMIN	APH	\$	0.0610
00002421836	ECL-METFORMIN	ECL	\$	0.0610
00002380218	JAMP-METFORMIN	JPC	\$	0.0610
00002380730	JAMP-METFORMIN BLACKBERRY	JPC	\$	0.0610
00002378639	MAR-METFORMIN	MAR	\$	0.0610
00002353385	METFORMIN	SNS	\$	0.0610
00002378868	METFORMIN	MAR	\$	0.0610
00002385368	METFORMIN FC	SIV	\$	0.0610
00002388774	MINT-METFORMIN	MPI	\$	0.0610
00002229656	MYLAN-METFORMIN	MYP	\$	0.0610
00002242589	PMS-METFORMIN	PMS	\$	0.0610
00002269058	RAN-METFORMIN	RAN	\$	0.0610
00002242931	RATIO-METFORMIN HYDROCHLORIDE	RPH	\$	0.0610
00002246821	SANDOZ METFORMIN FC	SDZ	\$	0.0610
00002379775	SEPTA-METFORMIN	SEP	\$	0.0610
00002230475	TEVA-METFORMIN	TEV	\$	0.0610
00002162849	GLUCOPHAGE	SAV	\$	0.3623

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

ALBERTA DRUG BENEFIT LIST UPDATE

OLANZAPINE

2.5 MG ORAL TABLET

00002325659	ACT OLANZAPINE	APH	\$	0.3189
00002281791	APO-OLANZAPINE	APX	\$	0.3189
00002421232	MAR-OLANZAPINE	MAR	\$	0.3189
00002337878	MYLAN-OLANZAPINE	MYP	\$	0.3189
00002372819	OLANZAPINE	SNS	\$	0.3189
00002385864	OLANZAPINE	SIV	\$	0.3189
00002303116	PMS-OLANZAPINE	PMS	\$	0.3189
00002403064	RAN-OLANZAPINE	RAN	\$	0.3189
00002310341	SANDOZ OLANZAPINE	SDZ	\$	0.3189
00002276712	TEVA-OLANZAPINE	TEV	\$	0.3189
00002229250	ZYPREXA	LIL	\$	1.7971

5 MG ORAL TABLET

00002325667	ACT OLANZAPINE	APH	\$	0.6379
00002281805	APO-OLANZAPINE	APX	\$	0.6379
00002421240	MAR-OLANZAPINE	MAR	\$	0.6379
00002337886	MYLAN-OLANZAPINE	MYP	\$	0.6379
00002372827	OLANZAPINE	SNS	\$	0.6379
00002385872	OLANZAPINE	SIV	\$	0.6379
00002303159	PMS-OLANZAPINE	PMS	\$	0.6379
00002403072	RAN-OLANZAPINE	RAN	\$	0.6379
00002310368	SANDOZ OLANZAPINE	SDZ	\$	0.6379
00002276720	TEVA-OLANZAPINE	TEV	\$	0.6379
00002229269	ZYPREXA	LIL	\$	3.5942

7.5 MG ORAL TABLET

00002325675	ACT OLANZAPINE	APH	\$	0.9568
00002281813	APO-OLANZAPINE	APX	\$	0.9568
00002421259	MAR-OLANZAPINE	MAR	\$	0.9568
00002337894	MYLAN-OLANZAPINE	MYP	\$	0.9568
00002372835	OLANZAPINE	SNS	\$	0.9568
00002385880	OLANZAPINE	SIV	\$	0.9568
00002303167	PMS-OLANZAPINE	PMS	\$	0.9568
00002403080	RAN-OLANZAPINE	RAN	\$	0.9568
00002310376	SANDOZ OLANZAPINE	SDZ	\$	0.9568
00002276739	TEVA-OLANZAPINE	TEV	\$	0.9568
00002229277	ZYPREXA	LIL	\$	5.3914

10 MG (BASE) ORAL TABLET

00002325683	ACT OLANZAPINE	APH	\$	1.2758
00002281821	APO-OLANZAPINE	APX	\$	1.2758
00002421267	MAR-OLANZAPINE	MAR	\$	1.2758
00002337908	MYLAN-OLANZAPINE	MYP	\$	1.2758
00002372843	OLANZAPINE	SNS	\$	1.2758
00002385899	OLANZAPINE	SIV	\$	1.2758
00002303175	PMS-OLANZAPINE	PMS	\$	1.2758
00002403099	RAN-OLANZAPINE	RAN	\$	1.2758
00002310384	SANDOZ OLANZAPINE	SDZ	\$	1.2758
00002276747	TEVA-OLANZAPINE	TEV	\$	1.2758
00002229285	ZYPREXA	LIL	\$	7.1889

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

ALBERTA DRUG BENEFIT LIST UPDATE

OLANZAPINE

15 MG ORAL TABLET

00002325691	ACT OLANZAPINE	APH	\$	1.9136
00002281848	APO-OLANZAPINE	APX	\$	1.9136
00002421275	MAR-OLANZAPINE	MAR	\$	1.9136
00002337916	MYLAN-OLANZAPINE	MYP	\$	1.9136
00002372851	OLANZAPINE	SNS	\$	1.9136
00002385902	OLANZAPINE	SIV	\$	1.9136
00002303183	PMS-OLANZAPINE	PMS	\$	1.9136
00002403102	RAN-OLANZAPINE	RAN	\$	1.9136
00002310392	SANDOZ OLANZAPINE	SDZ	\$	1.9136
00002276755	TEVA-OLANZAPINE	TEV	\$	1.9136
00002238850	ZYPREXA	LIL	\$	10.7832

5 MG ORAL DISINTEGRATING TABLET

00002414538	ABBOTT-OLANZAPINE ODT	ABB	\$	0.6434
00002360616	APO-OLANZAPINE ODT	APX	\$	0.6434
00002327562	CO OLANZAPINE ODT	APH	\$	0.6434
00002406624	JAMP-OLANZAPINE ODT	JPC	\$	0.6434
00002389088	MAR-OLANZAPINE ODT	MAR	\$	0.6434
00002382709	MYLAN-OLANZAPINE ODT	MYP	\$	0.6434
00002343665	OLANZAPINE ODT	SIV	\$	0.6434
00002352974	OLANZAPINE ODT	SNS	\$	0.6434
00002303191	PMS-OLANZAPINE ODT	PMS	\$	0.6434
00002414090	RAN-OLANZAPINE ODT	RAN	\$	0.6434
00002327775	SANDOZ OLANZAPINE ODT	SDZ	\$	0.6434
00002321343	TEVA-OLANZAPINE OD	TEV	\$	0.6434
00002243086	ZYPREXA ZYDIS	LIL	\$	3.5746

10 MG (BASE) ORAL DISINTEGRATING TABLET

00002414546	ABBOTT-OLANZAPINE ODT	ABB	\$	1.2857
00002360624	APO-OLANZAPINE ODT	APX	\$	1.2857
00002327570	CO OLANZAPINE ODT	APH	\$	1.2857
00002406632	JAMP-OLANZAPINE ODT	JPC	\$	1.2857
00002389096	MAR-OLANZAPINE ODT	MAR	\$	1.2857
00002382717	MYLAN-OLANZAPINE ODT	MYP	\$	1.2857
00002343673	OLANZAPINE ODT	SIV	\$	1.2857
00002352982	OLANZAPINE ODT	SNS	\$	1.2857
00002303205	PMS-OLANZAPINE ODT	PMS	\$	1.2857
00002414104	RAN-OLANZAPINE ODT	RAN	\$	1.2857
00002327783	SANDOZ OLANZAPINE ODT	SDZ	\$	1.2857
00002321351	TEVA-OLANZAPINE OD	TEV	\$	1.2857
00002243087	ZYPREXA ZYDIS	LIL	\$	7.1429

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

ALBERTA DRUG BENEFIT LIST UPDATE

OMEPRAZOLE

20 MG ORAL CAPSULE/SUSTAINED-RELEASE TABLET

00002245058	APO-OMEPRAZOLE (CAPSULE)	APX	\$	0.4117
00002422220	AURO-OMEPRAZOLE (DELAYED-RELEASE CAPSULE)	AUR	\$	0.4117
00002420198	JAMP-OMEPRAZOLE DR (DELAYED-RELEASE TABLET)	JPC	\$	0.4117
00002329433	MYLAN-OMEPRAZOLE (CAPSULE)	MYP	\$	0.4117
00002348691	OMEPRAZOLE (CAPSULE)	SNS	\$	0.4117
00002416549	OMEPRAZOLE (DELAYED-RELEASE TABLET)	AHI	\$	0.4117
00002411857	OMEPRAZOLE-20	SIV	\$	0.4117
00002320851	PMS-OMEPRAZOLE (SUSTAINED-RELEASE CAPSULE)	PMS	\$	0.4117
00002310260	PMS-OMEPRAZOLE DR (DELAYED RELEASE TABLET)	PMS	\$	0.4117
00002403617	RAN-OMEPRAZOLE (DELAYED-RELEASE CAPSULE)	RAN	\$	0.4117
00002374870	RAN-OMEPRAZOLE (DELAYED-RELEASE TABLET)	RAN	\$	0.4117
00002296446	SANDOZ OMEPRAZOLE (SUSTAINED-RELEASE CAPSULE)	SDZ	\$	0.4117
00002295415	TEVA-OMEPRAZOLE (DELAYED-RELEASE TABLET)	TEV	\$	0.4117
00000846503	LOSEC (SUSTAINED-RELEASE CAPSULE)	AZC	\$	1.1096
00002190915	LOSEC (SUSTAINED-RELEASE TABLET)	AZC	\$	2.3348

PANTOPRAZOLE

40 MG ORAL ENTERIC-COATED TABLET

00002412969	ABBOTT-PANTOPRAZOLE	ABB	\$	0.3628
00002300486	ACT PANTOPRAZOLE	APH	\$	0.3628
00002292920	APO-PANTOPRAZOLE	APX	\$	0.3628
00002415208	AURO-PANTOPRAZOLE	AUR	\$	0.3628
00002357054	JAMP-PANTOPRAZOLE	JPC	\$	0.3628
00002416565	MAR-PANTOPRAZOLE	MAR	\$	0.3628
00002417448	MINT-PANTOPRAZOLE	MPI	\$	0.3628
00002299585	MYLAN-PANTOPRAZOLE	MYP	\$	0.3628
00002370808	PANTOPRAZOLE	SNS	\$	0.3628
00002385759	PANTOPRAZOLE	SIV	\$	0.3628
00002307871	PMS-PANTOPRAZOLE	PMS	\$	0.3628
00002305046	RAN-PANTOPRAZOLE	RAN	\$	0.3628
00002301083	SANDOZ PANTOPRAZOLE	SDZ	\$	0.3628
00002285487	TEVA-PANTOPRAZOLE	TEV	\$	0.3628
☒ 00002267233	TECTA	TAK	\$	0.7500
00002229453	PANTOLOC	TAK	\$	2.0803

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

ALBERTA DRUG BENEFIT LIST UPDATE

RABEPRAZOLE SODIUM

10 MG ORAL ENTERIC-COATED TABLET

00002422638	ABBOTT-RABEPRAZOLE	ABB	\$	0.1204
00002345579	APO-RABEPRAZOLE	APX	\$	0.1204
00002408392	MYLAN-RABEPRAZOLE	MYP	\$	0.1204
00002310805	PMS-RABEPRAZOLE EC	PMS	\$	0.1204
00002385449	RABEPRAZOLE	SIV	\$	0.1204
00002356511	RABEPRAZOLE EC	SNS	\$	0.1204
00002298074	RAN-RABEPRAZOLE	RAN	\$	0.1204
00002314177	SANDOZ RABEPRAZOLE	SDZ	\$	0.1204
00002296632	TEVA-RABEPRAZOLE	TEV	\$	0.1204
00002243796	PARIET	JAI	\$	0.6688

20 MG ORAL ENTERIC-COATED TABLET

00002422646	ABBOTT-RABEPRAZOLE	ABB	\$	0.2408
00002345587	APO-RABEPRAZOLE	APX	\$	0.2408
00002408406	MYLAN-RABEPRAZOLE	MYP	\$	0.2408
00002310813	PMS-RABEPRAZOLE EC	PMS	\$	0.2408
00002385457	RABEPRAZOLE	SIV	\$	0.2408
00002356538	RABEPRAZOLE EC	SNS	\$	0.2408
00002298082	RAN-RABEPRAZOLE	RAN	\$	0.2408
00002314185	SANDOZ RABEPRAZOLE	SDZ	\$	0.2408
00002296640	TEVA-RABEPRAZOLE	TEV	\$	0.2408
00002243797	PARIET	JAI	\$	1.3377

RAMIPRIL

1.25 MG ORAL CAPSULE/TABLET

00002295482	ACT RAMIPRIL (CAPSULE)	APH	\$	0.1274
00002251515	APO-RAMIPRIL (CAPSULE)	APX	\$	0.1274
00002387387	AURO-RAMIPRIL (CAPSULE)	AUR	\$	0.1274
00002331101	JAMP-RAMIPRIL (CAPSULE)	JPC	\$	0.1274
00002420457	MAR-RAMIPRIL (CAPSULE)	MAR	\$	0.1274
00002301148	MYLAN-RAMIPRIL (CAPSULE)	MYP	\$	0.1274
00002295369	PMS-RAMIPRIL (CAPSULE)	PMS	\$	0.1274
00002332299	RAMIPRIL (CAPSULE)	RAN	\$	0.1274
00002310503	RAN-RAMIPRIL (CAPSULE)	RAN	\$	0.1274
00002291398	SANDOZ RAMIPRIL (TABLET)	SDZ	\$	0.1274
00002221829	ALTACE (CAPSULE)	SAV	\$	0.7240

2.5 MG ORAL CAPSULE/TABLET

00002295490	ACT RAMIPRIL (CAPSULE)	APH	\$	0.1470
00002251531	APO-RAMIPRIL (CAPSULE)	APX	\$	0.1470
00002387395	AURO-RAMIPRIL (CAPSULE)	AUR	\$	0.1470
00002331128	JAMP-RAMIPRIL (CAPSULE)	JPC	\$	0.1470
00002420465	MAR-RAMIPRIL (CAPSULE)	MAR	\$	0.1470
00002421305	MINT-RAMIPRIL (CAPSULE)	MPI	\$	0.1470
00002301156	MYLAN-RAMIPRIL (CAPSULE)	MYP	\$	0.1470
00002247917	PMS-RAMIPRIL (CAPSULE)	PMS	\$	0.1470
00002332302	RAMIPRIL (CAPSULE)	RAN	\$	0.1470
00002374846	RAMIPRIL (CAPSULE)	SNS	\$	0.1470
00002411563	RAMIPRIL-2.5 (CAPSULE)	SIV	\$	0.1470
00002310511	RAN-RAMIPRIL (CAPSULE)	RAN	\$	0.1470
00002291401	SANDOZ RAMIPRIL (TABLET)	SDZ	\$	0.1470
00002247945	TEVA-RAMIPRIL (CAPSULE)	TEV	\$	0.1470
00002221837	ALTACE (CAPSULE)	SAV	\$	0.8310

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

ALBERTA DRUG BENEFIT LIST UPDATE

RAMIPRIL

5 MG ORAL CAPSULE/TABLET

00002295504	ACT RAMIPRIL (CAPSULE)	APH	\$	0.1470
00002251574	APO-RAMIPRIL (CAPSULE)	APX	\$	0.1470
00002387409	AURO-RAMIPRIL (CAPSULE)	AUR	\$	0.1470
00002331136	JAMP-RAMIPRIL (CAPSULE)	JPC	\$	0.1470
00002420473	MAR-RAMIPRIL (CAPSULE)	MAR	\$	0.1470
00002421313	MINT-RAMIPRIL (CAPSULE)	MPI	\$	0.1470
00002301164	MYLAN-RAMIPRIL (CAPSULE)	MYP	\$	0.1470
00002247918	PMS-RAMIPRIL (CAPSULE)	PMS	\$	0.1470
00002332310	RAMIPRIL (CAPSULE)	RAN	\$	0.1470
00002374854	RAMIPRIL (CAPSULE)	SNS	\$	0.1470
00002411571	RAMIPRIL-5 (CAPSULE)	SIV	\$	0.1470
00002310538	RAN-RAMIPRIL (CAPSULE)	RAN	\$	0.1470
00002291428	SANDOZ RAMIPRIL (TABLET)	SDZ	\$	0.1470
00002247946	TEVA-RAMIPRIL (CAPSULE)	TEV	\$	0.1470
00002221845	ALTACE (CAPSULE)	SAV	\$	0.8320

10 MG ORAL CAPSULE/TABLET

00002295512	ACT RAMIPRIL (CAPSULE)	APH	\$	0.1862
00002251582	APO-RAMIPRIL (CAPSULE)	APX	\$	0.1862
00002387417	AURO-RAMIPRIL (CAPSULE)	AUR	\$	0.1862
00002331144	JAMP-RAMIPRIL (CAPSULE)	JPC	\$	0.1862
00002420481	MAR-RAMIPRIL (CAPSULE)	MAR	\$	0.1862
00002421321	MINT-RAMIPRIL (CAPSULE)	MPI	\$	0.1862
00002301172	MYLAN-RAMIPRIL (CAPSULE)	MYP	\$	0.1862
00002247919	PMS-RAMIPRIL (CAPSULE)	PMS	\$	0.1862
00002332329	RAMIPRIL (CAPSULE)	RAN	\$	0.1862
00002374862	RAMIPRIL (CAPSULE)	SNS	\$	0.1862
00002411598	RAMIPRIL-10 (CAPSULE)	SIV	\$	0.1862
00002310546	RAN-RAMIPRIL (CAPSULE)	RAN	\$	0.1862
00002291436	SANDOZ RAMIPRIL (TABLET)	SDZ	\$	0.1862
00002247947	TEVA-RAMIPRIL (CAPSULE)	TEV	\$	0.1862
00002221853	ALTACE (CAPSULE)	SAV	\$	1.0553

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

ALBERTA DRUG BENEFIT LIST UPDATE

ROSUVASTATIN CALCIUM

5 MG (BASE) ORAL TABLET

00002337975	APO-ROSUVASTATIN	APX	\$	0.2311
00002339765	CO ROSUVASTATIN	APH	\$	0.2311
00002391252	JAMP-ROSUVASTATIN	JPC	\$	0.2311
00002413051	MAR-ROSUVASTATIN	MAR	\$	0.2311
00002399164	MED-ROSUVASTATIN	GMP	\$	0.2311
00002397781	MINT-ROSUVASTATIN	MPI	\$	0.2311
00002381265	MYLAN-ROSUVASTATIN	MYP	\$	0.2311
00002378523	PMS-ROSUVASTATIN	PMS	\$	0.2311
00002382644	RAN-ROSUVASTATIN	RAN	\$	0.2311
00002405628	ROSUVASTATIN	SNS	\$	0.2311
00002411628	ROSUVASTATIN-5	SIV	\$	0.2311
00002338726	SANDOZ ROSUVASTATIN	SDZ	\$	0.2311
00002354608	TEVA-ROSUVASTATIN	TEV	\$	0.2311
00002265540	CRESTOR	AZC	\$	1.3210

10 MG (BASE) ORAL TABLET

00002337983	APO-ROSUVASTATIN	APX	\$	0.2437
00002339773	CO ROSUVASTATIN	APH	\$	0.2437
00002391260	JAMP-ROSUVASTATIN	JPC	\$	0.2437
00002413078	MAR-ROSUVASTATIN	MAR	\$	0.2437
00002399172	MED-ROSUVASTATIN	GMP	\$	0.2437
00002397803	MINT-ROSUVASTATIN	MPI	\$	0.2437
00002381273	MYLAN-ROSUVASTATIN	MYP	\$	0.2437
00002378531	PMS-ROSUVASTATIN	PMS	\$	0.2437
00002382652	RAN-ROSUVASTATIN	RAN	\$	0.2437
00002405636	ROSUVASTATIN	SNS	\$	0.2437
00002411636	ROSUVASTATIN-10	SIV	\$	0.2437
00002338734	SANDOZ ROSUVASTATIN	SDZ	\$	0.2437
00002354616	TEVA-ROSUVASTATIN	TEV	\$	0.2437
00002247162	CRESTOR	AZC	\$	1.3722

20 MG (BASE) ORAL TABLET

00002337991	APO-ROSUVASTATIN	APX	\$	0.3046
00002339781	CO ROSUVASTATIN	APH	\$	0.3046
00002391279	JAMP-ROSUVASTATIN	JPC	\$	0.3046
00002413086	MAR-ROSUVASTATIN	MAR	\$	0.3046
00002399180	MED-ROSUVASTATIN	GMP	\$	0.3046
00002397811	MINT-ROSUVASTATIN	MPI	\$	0.3046
00002381281	MYLAN-ROSUVASTATIN	MYP	\$	0.3046
00002378558	PMS-ROSUVASTATIN	PMS	\$	0.3046
00002382660	RAN-ROSUVASTATIN	RAN	\$	0.3046
00002405644	ROSUVASTATIN	SNS	\$	0.3046
00002411644	ROSUVASTATIN-20	SIV	\$	0.3046
00002338742	SANDOZ ROSUVASTATIN	SDZ	\$	0.3046
00002354624	TEVA-ROSUVASTATIN	TEV	\$	0.3046
00002247163	CRESTOR	AZC	\$	1.7152

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

ALBERTA DRUG BENEFIT LIST UPDATE

ROSUVASTATIN CALCIUM

40 MG (BASE) ORAL TABLET

00002338009	APO-ROSUVASTATIN	APX	\$	0.3582
00002339803	CO ROSUVASTATIN	APH	\$	0.3582
00002391287	JAMP-ROSUVASTATIN	JPC	\$	0.3582
00002413108	MAR-ROSUVASTATIN	MAR	\$	0.3582
00002399199	MED-ROSUVASTATIN	GMP	\$	0.3582
00002397838	MINT-ROSUVASTATIN	MPI	\$	0.3582
00002381303	MYLAN-ROSUVASTATIN	MYP	\$	0.3582
00002378566	PMS-ROSUVASTATIN	PMS	\$	0.3582
00002382679	RAN-ROSUVASTATIN	RAN	\$	0.3582
00002405652	ROSUVASTATIN	SNS	\$	0.3582
00002411652	ROSUVASTATIN-40	SIV	\$	0.3582
00002338750	SANDOZ ROSUVASTATIN	SDZ	\$	0.3582
00002354632	TEVA-ROSUVASTATIN	TEV	\$	0.3582
00002247164	CRESTOR	AZC	\$	2.0076

SIMVASTATIN

5 MG ORAL TABLET

00002248103	ACT SIMVASTATIN	APH	\$	0.1841
00002247011	APO-SIMVASTATIN	APX	\$	0.1841
00002375591	JAMP-SIMVASTATIN	JPC	\$	0.1841
00002375036	MAR-SIMVASTATIN	MAR	\$	0.1841
00002372932	MINT-SIMVASTATIN	MPI	\$	0.1841
00002246582	MYLAN-SIMVASTATIN	MYP	\$	0.1841
00002269252	PMS-SIMVASTATIN	PMS	\$	0.1841
00002329131	RAN-SIMVASTATIN	RAN	\$	0.1841
00002284723	SIMVASTATIN	SNS	\$	0.1841
00002331969	SIMVASTATIN	RAN	\$	0.1841
00002386291	SIMVASTATIN	SIV	\$	0.1841
00002250144	TEVA-SIMVASTATIN	TEV	\$	0.1841
00000884324	ZOCOR	MFC	\$	1.0840

10 MG ORAL TABLET

00002248104	ACT SIMVASTATIN	APH	\$	0.3642
00002247012	APO-SIMVASTATIN	APX	\$	0.3642
00002375605	JAMP-SIMVASTATIN	JPC	\$	0.3642
00002375044	MAR-SIMVASTATIN	MAR	\$	0.3642
00002372940	MINT-SIMVASTATIN	MPI	\$	0.3642
00002246583	MYLAN-SIMVASTATIN	MYP	\$	0.3642
00002269260	PMS-SIMVASTATIN	PMS	\$	0.3642
00002329158	RAN-SIMVASTATIN	RAN	\$	0.3642
00002284731	SIMVASTATIN	SNS	\$	0.3642
00002331985	SIMVASTATIN	RAN	\$	0.3642
00002386305	SIMVASTATIN	SIV	\$	0.3642
00002250152	TEVA-SIMVASTATIN	TEV	\$	0.3642
00000884332	ZOCOR	MFC	\$	2.1321

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

ALBERTA DRUG BENEFIT LIST UPDATE

SIMVASTATIN

20 MG ORAL TABLET

00002248105	ACT SIMVASTATIN	APH	\$	0.4501
00002247013	APO-SIMVASTATIN	APX	\$	0.4501
00002375613	JAMP-SIMVASTATIN	JPC	\$	0.4501
00002375052	MAR-SIMVASTATIN	MAR	\$	0.4501
00002372959	MINT-SIMVASTATIN	MPI	\$	0.4501
00002246737	MYLAN-SIMVASTATIN	MYP	\$	0.4501
00002269279	PMS-SIMVASTATIN	PMS	\$	0.4501
00002329166	RAN-SIMVASTATIN	RAN	\$	0.4501
00002284758	SIMVASTATIN	SNS	\$	0.4501
00002331993	SIMVASTATIN	RAN	\$	0.4501
00002386313	SIMVASTATIN	SIV	\$	0.4501
00002250160	TEVA-SIMVASTATIN	TEV	\$	0.4501
00000884340	ZOCOR	MFC	\$	2.6350

40 MG ORAL TABLET

00002248106	ACT SIMVASTATIN	APH	\$	0.4501
00002247014	APO-SIMVASTATIN	APX	\$	0.4501
00002375621	JAMP-SIMVASTATIN	JPC	\$	0.4501
00002375060	MAR-SIMVASTATIN	MAR	\$	0.4501
00002372967	MINT-SIMVASTATIN	MPI	\$	0.4501
00002246584	MYLAN-SIMVASTATIN	MYP	\$	0.4501
00002269287	PMS-SIMVASTATIN	PMS	\$	0.4501
00002329174	RAN-SIMVASTATIN	RAN	\$	0.4501
00002284766	SIMVASTATIN	SNS	\$	0.4501
00002332000	SIMVASTATIN	RAN	\$	0.4501
00002386321	SIMVASTATIN	SIV	\$	0.4501
00002250179	TEVA-SIMVASTATIN	TEV	\$	0.4501
00000884359	ZOCOR	MFC	\$	2.6350

80 MG ORAL TABLET

00002248107	ACT SIMVASTATIN	APH	\$	0.4501
00002247015	APO-SIMVASTATIN	APX	\$	0.4501
00002375648	JAMP-SIMVASTATIN	JPC	\$	0.4501
00002375079	MAR-SIMVASTATIN	MAR	\$	0.4501
00002372975	MINT-SIMVASTATIN	MPI	\$	0.4501
00002246585	MYLAN-SIMVASTATIN	MYP	\$	0.4501
00002269295	PMS-SIMVASTATIN	PMS	\$	0.4501
00002329182	RAN-SIMVASTATIN	RAN	\$	0.4501
00002284774	SIMVASTATIN	SNS	\$	0.4501
00002332019	SIMVASTATIN	RAN	\$	0.4501
00002386348	SIMVASTATIN	SIV	\$	0.4501
00002250187	TEVA-SIMVASTATIN	TEV	\$	0.4501

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

ALBERTA DRUG BENEFIT LIST UPDATE

VENLAFAXINE HCL

37.5 MG (BASE) ORAL EXTENDED-RELEASE CAPSULE			
00002304317	ACT VENLAFAXINE XR	APH	\$ 0.1643
00002331683	APO-VENLAFAXINE XR	APX	\$ 0.1643
00002360020	GD-VENLAFAXINE XR	GMD	\$ 0.1643
00002310279	MYLAN-VENLAFAXINE XR	MYP	\$ 0.1643
00002278545	PMS-VENLAFAXINE XR	PMS	\$ 0.1643
00002380072	RAN-VENLAFAXINE XR	RAN	\$ 0.1643
00002310317	SANDOZ VENLAFAXINE XR	SDZ	\$ 0.1643
00002275023	TEVA-VENLAFAXINE XR	TEV	\$ 0.1643
00002354713	VENLAFAXINE XR	SNS	\$ 0.1643
00002385929	VENLAFAXINE XR	SIV	\$ 0.1643
00002237279	EFFEXOR XR	PFI	\$ 0.9381
75 MG (BASE) ORAL EXTENDED-RELEASE CAPSULE			
00002304325	ACT VENLAFAXINE XR	APH	\$ 0.3285
00002331691	APO-VENLAFAXINE XR	APX	\$ 0.3285
00002360039	GD-VENLAFAXINE XR	GMD	\$ 0.3285
00002310287	MYLAN-VENLAFAXINE XR	MYP	\$ 0.3285
00002278553	PMS-VENLAFAXINE XR	PMS	\$ 0.3285
00002380080	RAN-VENLAFAXINE XR	RAN	\$ 0.3285
00002310325	SANDOZ VENLAFAXINE XR	SDZ	\$ 0.3285
00002275031	TEVA-VENLAFAXINE XR	TEV	\$ 0.3285
00002354721	VENLAFAXINE XR	SNS	\$ 0.3285
00002385937	VENLAFAXINE XR	SIV	\$ 0.3285
00002237280	EFFEXOR XR	PFI	\$ 1.8765
150 MG (BASE) ORAL EXTENDED-RELEASE CAPSULE			
00002304333	ACT VENLAFAXINE XR	APH	\$ 0.3469
00002331705	APO-VENLAFAXINE XR	APX	\$ 0.3469
00002360047	GD-VENLAFAXINE XR	GMD	\$ 0.3469
00002310295	MYLAN-VENLAFAXINE XR	MYP	\$ 0.3469
00002278561	PMS-VENLAFAXINE XR	PMS	\$ 0.3469
00002380099	RAN-VENLAFAXINE XR	RAN	\$ 0.3469
00002310333	SANDOZ VENLAFAXINE XR	SDZ	\$ 0.3469
00002275058	TEVA-VENLAFAXINE XR	TEV	\$ 0.3469
00002354748	VENLAFAXINE XR	SNS	\$ 0.3469
00002385945	VENLAFAXINE XR	SIV	\$ 0.3469
00002237282	EFFEXOR XR	PFI	\$ 1.9810

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

PART 3

Special Authorization

**ALBERTA DRUG BENEFIT LIST UPDATE
CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS**

CLOPIDOGREL BISULFATE

(Refer to 20:12.18 of the Alberta Drug Benefit List for one month of coverage, following the first intravascular stent placement, when prescribed by a Specialist in Cardiology, Cardiac Surgery, Cardiovascular & Thoracic Surgery, or General Surgery.)

"For the prevention of thrombosis, for one month, when prescribed following intravascular bare metal stent placement. Patients who have received one month of coverage via the Limited Restricted Benefit will not be eligible for additional coverage under this criterion."*

"For the prevention of thrombosis, for up to 12 months, when prescribed following intravascular drug eluting stent (DES) placement. Patients who have received one month of coverage via the Limited Restricted Benefit may be eligible for an additional 11 months of coverage (i.e., up to 12 months of coverage) following the submission of a special authorization request."**

"For the prevention of ischemic events (cerebrovascular (e.g. stroke, TIA) or noncerebrovascular) in patients who have experienced an ischemic event while on ASA, or who have a contraindication to ASA. Special authorization for this criterion may be granted for 6 months."**

"Coverage will not be considered when clopidogrel and dipyridamole/ASA are intended for use in combination."

* Special Authorization for post-stent coverage is required when the prescriber prescribing the medication is not a Specialist in Cardiology, Cardiac Surgery, Cardiovascular & Thoracic Surgery, or General Surgery; for treatment after repeat stents; or for continued coverage of up to 12 months following intravascular drug eluting stent (DES) placement.

In order to comply with the first and second criteria, information is required regarding the date, type of stent, and stenting procedure. In order to comply with the third criterion, information is required regarding the type of ischemic event experienced while on ASA and, if applicable, information is required as to why ASA cannot be used.

All requests for clopidogrel bisulfate must be completed using the Clopidogrel Special Authorization Request Form (ABC 30786).

** The following product(s) are eligible for auto-renewal for the third criterion only.

75 MG (BASE)	ORAL	TABLET			
00002412942	ABBOTT-CLOPIDOGREL	ABB	\$	0.4735	
00002252767	APO-CLOPIDOGREL	APX	\$	0.4735	
00002416387	AURO-CLOPIDOGREL	AUR	\$	0.4735	
00002385813	CLOPIDOGREL	SIV	\$	0.4735	
00002400553	CLOPIDOGREL	SNS	\$	0.4735	
00002303027	CO CLOPIDOGREL	APH	\$	0.4735	
00002415550	JAMP-CLOPIDOGREL	JPC	\$	0.4735	
00002422255	MAR-CLOPIDOGREL	MAR	\$	0.4735	
00002408910	MINT-CLOPIDOGREL	MPI	\$	0.4735	
00002351536	MYLAN-CLOPIDOGREL	MYP	\$	0.4735	
00002348004	PMS-CLOPIDOGREL	PMS	\$	0.4735	
00002379813	RAN-CLOPIDOGREL	RAN	\$	0.4735	
00002359316	SANDOZ CLOPIDOGREL	SDZ	\$	0.4735	
00002293161	TEVA-CLOPIDOGREL	TEV	\$	0.4735	
00002238682	PLAVIX	SAV	\$	2.7125	